# A Trial of HRS-5965 Tablets in Primary IgA Nephropathy

> **NCT06137768** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Chengdu Suncadia Medicine Co., Ltd.** · enrollment: 123 (actual)

## Conditions studied

- Primary IgA Nephropathy

## Interventions

- **DRUG:** HRS-5965
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06137768
- **Lead sponsor:** Chengdu Suncadia Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-12-19
- **Primary completion:** 2024-12-01
- **Final completion:** 2025-08-31
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2025-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06137768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06137768, "A Trial of HRS-5965 Tablets in Primary IgA Nephropathy". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT06137768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*